$QURE
uniQure N.V.

2021 Q4 Form 10-Q Financial Statement

#000155837021013423 Filed on October 25, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q4
Revenue $57.69M $1.989M $34.09M
YoY Change 69.23% 11.18% 1196.2%
Cost Of Revenue $1.798M $0.00
YoY Change
Gross Profit $55.89M $1.989M
YoY Change
Gross Profit Margin 96.88% 100.0%
Selling, General & Admin $13.97M $12.02M $11.21M
YoY Change 24.59% 11.44% 29.15%
% of Gross Profit 24.99% 604.47%
Research & Development $42.34M $36.43M $31.68M
YoY Change 33.65% 0.36% 19.59%
% of Gross Profit 75.75% 1831.67%
Depreciation & Amortization $1.852M $1.780M $2.300M
YoY Change -19.48% -63.22% 32.18%
% of Gross Profit 3.31% 89.49%
Operating Expenses $53.82M $48.46M $42.35M
YoY Change 27.1% 2.9% 18.96%
Operating Profit $2.068M -$45.00M
YoY Change 1.15%
Interest Expense $5.957M $1.924M -$6.810M
YoY Change -187.47% 104.25% 0.44%
% of Operating Profit 288.06%
Other Income/Expense, Net -$160.0K $214.0K -$2.050M
YoY Change -92.2% -2.73% 22.75%
Pretax Income $7.865M -$36.44M -$17.12M
YoY Change -145.94% -32.23% -58.68%
Income Tax -$343.0K $100.0K -$16.42M
% Of Pretax Income -4.36%
Net Earnings $8.208M -$36.53M -$700.0K
YoY Change -1272.57% -32.07% -98.31%
Net Earnings / Revenue 14.23% -1836.65% -2.05%
Basic Earnings Per Share -$0.79
Diluted Earnings Per Share $174.6K -$0.79 -$15.65K
COMMON SHARES
Basic Shares Outstanding 46.21M 46.15M 44.50M
Diluted Shares Outstanding 46.15M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $556.3M $578.5M $244.9M
YoY Change 127.14% 106.96% -35.18%
Cash & Equivalents $556.3M $578.5M $244.9M
Short-Term Investments
Other Short-Term Assets $13.22M $11.53M $3.024M
YoY Change 337.0% 49.73% 304.28%
Inventory
Prepaid Expenses $10.54M $10.35M $4.337M
Receivables $58.77M $3.771M $6.618M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $628.2M $593.8M $258.9M
YoY Change 142.65% 106.61% -32.61%
LONG-TERM ASSETS
Property, Plant & Equipment $43.51M $41.22M $32.33M
YoY Change 34.57% 39.07% 12.36%
Goodwill $27.63M $28.06M $542.0K
YoY Change 4998.34% 5316.99% 9.27%
Intangibles $62.69M $64.01M $3.361M
YoY Change 1765.1%
Long-Term Investments
YoY Change
Other Assets $5.897M $5.668M $2.748M
YoY Change 114.59% 109.93% -5.24%
Total Long-Term Assets $180.9M $180.9M $81.48M
YoY Change 122.06% 186.5% 26.48%
TOTAL ASSETS
Total Short-Term Assets $628.2M $593.8M $258.9M
Total Long-Term Assets $180.9M $180.9M $81.48M
Total Assets $809.2M $774.6M $340.4M
YoY Change 137.72% 121.0% -24.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.502M $5.373M $3.772M
YoY Change -33.67% 128.83% -33.6%
Accrued Expenses $28.49M $30.75M $18.04M
YoY Change 57.93% 72.89% 44.8%
Deferred Revenue $2.082M
YoY Change -72.7%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $36.76M $41.92M $27.33M
YoY Change 34.5% 25.69% -13.58%
LONG-TERM LIABILITIES
Long-Term Debt $101.0M $71.49M $35.62M
YoY Change 183.47% 101.41% -1.23%
Other Long-Term Liabilities $4.236M $3.808M $3.136M
YoY Change 35.08% 698.32% 487.27%
Total Long-Term Liabilities $176.6M $142.0M $69.16M
YoY Change 155.42% 59.03% -26.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $36.76M $41.92M $27.33M
Total Long-Term Liabilities $176.6M $142.0M $69.16M
Total Liabilities $213.4M $183.9M $96.49M
YoY Change 121.17% 49.96% -23.16%
SHAREHOLDERS EQUITY
Retained Earnings -$455.1M -$463.4M -$784.7M
YoY Change -42.0% -40.9% 18.95%
Common Stock $2.802M $2.797M $2.711M
YoY Change 3.36% 3.82% 2.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $595.8M $590.8M $243.9M
YoY Change
Total Liabilities & Shareholders Equity $809.2M $774.6M $340.4M
YoY Change 137.72% 121.0% -24.13%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q4
OPERATING ACTIVITIES
Net Income $8.208M -$36.53M -$700.0K
YoY Change -1272.57% -32.07% -98.31%
Depreciation, Depletion And Amortization $1.852M $1.780M $2.300M
YoY Change -19.48% -63.22% 32.18%
Cash From Operating Activities -$47.09M -$40.16M -$37.18M
YoY Change 26.65% 15.69% 43.0%
INVESTING ACTIVITIES
Capital Expenditures -$3.553M -$7.694M -$2.690M
YoY Change 32.08% 252.94% 36.55%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$49.95M
YoY Change
Cash From Investing Activities -$3.553M -$57.64M -$2.690M
YoY Change 32.08% 2544.17% 36.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 29.89M -164.0K 3.750M
YoY Change 697.17% -217.14% 186.26%
NET CHANGE
Cash From Operating Activities -47.09M -40.16M -37.18M
Cash From Investing Activities -3.553M -57.64M -2.690M
Cash From Financing Activities 29.89M -164.0K 3.750M
Net Change In Cash -20.75M -97.96M -36.12M
YoY Change -42.56% 166.57% 35.48%
FREE CASH FLOW
Cash From Operating Activities -$47.09M -$40.16M -$37.18M
Capital Expenditures -$3.553M -$7.694M -$2.690M
Free Cash Flow -$43.54M -$32.46M -$34.49M
YoY Change 26.23% -0.21% 43.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
1105 BP
dei Entity Address City Or Town
EntityAddressCityOrTown
Amsterdam
dei Entity Address Country
EntityAddressCountry
NL
dei City Area Code
CityAreaCode
31
dei Local Phone Number
LocalPhoneNumber
20-240-6000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3136000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.05
CY2020Q3 us-gaap Interest Expense
InterestExpense
942000
us-gaap Interest Expense
InterestExpense
5377000
us-gaap Interest Expense
InterestExpense
2887000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
325000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2531000
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46207776
dei Entity Central Index Key
EntityCentralIndexKey
0001590560
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44777799
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36294
dei Entity Registrant Name
EntityRegistrantName
uniQure N.V.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
P7
dei Entity Address Address Line1
EntityAddressAddressLine1
Paasheuvelweg 25
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-124325000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
9022000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3541000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16450000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
147000
CY2021Q3 qure Other Current Assets And Receivables
OtherCurrentAssetsAndReceivables
1184000
CY2020Q4 qure Other Current Assets And Receivables
OtherCurrentAssetsAndReceivables
3024000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
293591000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-115303000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.79
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.21
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
7.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.80
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.79
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
6.87
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.80
dei Security12b Title
Security12bTitle
Ordinary Shares, par value €0.05
dei Trading Symbol
TradingSymbol
QURE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
46214244
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
578464000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
244932000
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3771000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6618000
CY2021Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
10345000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4337000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.05
CY2021Q3 us-gaap Assets Current
AssetsCurrent
593764000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
258911000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
35900000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
35200000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
41215000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32328000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26194000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26086000
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
64005000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3361000
CY2021Q3 us-gaap Goodwill
Goodwill
28060000
CY2020Q4 us-gaap Goodwill
Goodwill
542000
CY2021Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
15719000
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
16419000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5668000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2748000
CY2021Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
180861000
CY2020Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
81484000
CY2021Q3 us-gaap Assets
Assets
774625000
CY2020Q4 us-gaap Assets
Assets
340395000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5373000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3772000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30746000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18038000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5798000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5524000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
41917000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
27334000
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
71490000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
35617000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
29733000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30403000
CY2021Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
23781000
CY2021Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
13141000
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3808000
CY2021Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
141953000
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
69156000
CY2021Q3 us-gaap Liabilities
Liabilities
183870000
CY2020Q4 us-gaap Liabilities
Liabilities
96490000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46207776
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44777799
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
2797000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
2711000
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1069191000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1016018000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-17883000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
9907000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-463350000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-784731000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
590755000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
243905000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
774625000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
340395000
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1989000
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1789000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
466311000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3428000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
23178000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36432000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36302000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
101209000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
90716000
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12023000
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10789000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
42323000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
31372000
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
48455000
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
47091000
us-gaap Costs And Expenses
CostsAndExpenses
166710000
us-gaap Costs And Expenses
CostsAndExpenses
122088000
CY2021Q3 us-gaap Other Income
OtherIncome
1680000
CY2020Q3 us-gaap Other Income
OtherIncome
1032000
us-gaap Other Income
OtherIncome
9622000
us-gaap Other Income
OtherIncome
2558000
CY2021Q3 us-gaap Other Expenses
OtherExpenses
214000
CY2020Q3 us-gaap Other Expenses
OtherExpenses
220000
us-gaap Other Expenses
OtherExpenses
673000
us-gaap Other Expenses
OtherExpenses
1059000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-45000000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-44490000
us-gaap Operating Income Loss
OperatingIncomeLoss
308550000
us-gaap Operating Income Loss
OperatingIncomeLoss
-117161000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
46000
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
13000
us-gaap Investment Income Interest
InvestmentIncomeInterest
123000
us-gaap Investment Income Interest
InvestmentIncomeInterest
916000
CY2021Q3 us-gaap Interest Expense
InterestExpense
1924000
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
10436000
CY2020Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-8681000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
21645000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-7724000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-36442000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-53775000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
324941000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-124325000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
89000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3560000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-36531000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-53775000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
321381000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-124325000
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-13288000
CY2020Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
9652000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-27790000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
9022000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-49819000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44123000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46152404
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44471844
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45888769
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44379924
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46152404
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44471844
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46780963
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44379924
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
265505000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-53775000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
9652000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
139000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6372000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
227893000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
633608000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-36531000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-13288000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
914000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5955000
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
97000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
590755000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
323058000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3630000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
335049000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-97653000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
49949000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
2314000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13885000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
227893000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
243905000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
321381000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-27790000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
29565000
qure Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Tax Effect Prior Years
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears
2977000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1824000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18747000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
146000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
590755000
us-gaap Profit Loss
ProfitLoss
321381000
us-gaap Profit Loss
ProfitLoss
-124325000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
5447000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
8354000
us-gaap Share Based Compensation
ShareBasedCompensation
18747000
us-gaap Share Based Compensation
ShareBasedCompensation
16450000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
3560000
qure Change In Fair Value Of Derivative Financial Instruments And Contingent Consideration
ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration
416000
qure Change In Fair Value Of Derivative Financial Instruments And Contingent Consideration
ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration
-2531000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
23242000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-7758000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
2862000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
2082000
qure Increase Decrease In Accounts Receivable Prepaid Expense And Other Current Assets
IncreaseDecreaseInAccountsReceivablePrepaidExpenseAndOtherCurrentAssets
1993000
qure Increase Decrease In Accounts Receivable Prepaid Expense And Other Current Assets
IncreaseDecreaseInAccountsReceivablePrepaidExpenseAndOtherCurrentAssets
1183000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2003000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3724000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
11592000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4475000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-63834000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6789000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
34603000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
30899000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1334000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1971000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3688000
us-gaap Repayments Of Debt
RepaymentsOfDebt
1175000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
64964000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3688000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-2589000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2235000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
333590000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-98519000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
247680000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
380726000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
581270000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
282207000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
578464000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
279493000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2806000
CY2020Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2714000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
581270000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
282207000
us-gaap Interest Paid Net
InterestPaidNet
4503000
us-gaap Interest Paid Net
InterestPaidNet
3342000
qure Increase Decrease In Accounts Payable And Accrued Liabilities Related To Non Current Assets
IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets
415000
qure Increase Decrease In Accounts Payable And Accrued Liabilities Related To Non Current Assets
IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets
116000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">1</b></span>General business information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">uniQure (the “Company”) was incorporated on January 9, 2012 as a private company with limited liability (<i style="font-style:italic;">besloten vennootschap met beperkte aansprakelijkheid</i>) under the laws of the Netherlands. The Company is a leader in the field of gene therapy and seeks to deliver to patients suffering from rare and other devastating diseases single treatments with potentially curative results. The Company’s business was founded in 1998 and was initially operated through its predecessor company, Amsterdam Molecular Therapeutics (AMT) Holding N.V (“AMT”). In 2012, AMT undertook a corporate reorganization, pursuant to which uniQure B.V. acquired the entire business and assets of AMT and completed a share-for-share exchange with the shareholders of AMT. Effective February 10, 2014, in connection with its initial public offering, the Company converted into a public company with limited liability (<i style="font-style:italic;">naamloze vennootschap</i>) and changed its legal name from uniQure B.V. to uniQure N.V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 1pt 0pt 1pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company is registered in the trade register of the Chamber of Commerce (<i style="font-style:italic;">Kamer van Koophandel</i>) in Amsterdam, the Netherlands under number 54385229. The Company’s headquarters are in Amsterdam, the Netherlands, and its registered office is located at Paasheuvelweg 25, Amsterdam 1105 BP, the Netherlands and its telephone number is +31 20 240 6000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s ordinary shares are listed on the Nasdaq Global Select Market and trade under the symbol “QURE”.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">2.3</b></span><b style="font-weight:bold;">Use of estimates </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</p>
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
64005000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3361000
CY2021Q3 qure Number Of Warrant Types
NumberOfWarrantTypes
2
qure Number Of Collaboration Targets
NumberOfCollaborationTargets
4
CY2021Q3 qure Collaboration Agreement Cash Payable
CollaborationAgreementCashPayable
70000000.0
CY2021Q3 qure Collaboration Agreement Cash Payable
CollaborationAgreementCashPayable
70000000.0
CY2020Q4 qure Collaboration Agreement Cash Payable
CollaborationAgreementCashPayable
70000000.0
CY2021Q3 qure Accruals For Services Provided By Vendors Not Yet Billed Current
AccrualsForServicesProvidedByVendorsNotYetBilledCurrent
19846000
CY2020Q4 qure Accruals For Services Provided By Vendors Not Yet Billed Current
AccrualsForServicesProvidedByVendorsNotYetBilledCurrent
8269000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10900000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7687000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2082000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30746000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18038000
CY2021Q3 qure Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Tax Effect Prior Years
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears
0
qure Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Tax Effect Prior Years
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears
3000000.0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
23200000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1800000
CY2021Q3 us-gaap Other Income
OtherIncome
1700000
us-gaap Other Income
OtherIncome
9600000
CY2020Q3 us-gaap Other Income
OtherIncome
1000000.0
us-gaap Other Income
OtherIncome
2600000
CY2021Q3 qure Employee Retention Credit Income
EmployeeRetentionCreditIncome
1300000
qure Employee Retention Credit Income
EmployeeRetentionCreditIncome
2600000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3600000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
qure Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Tax Effect Prior Years
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears
3000000.0
CY2021Q3 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
200000
CY2021Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.002
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.011
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.25
CY2021Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.25
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-36531000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-53775000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
321381000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-124325000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-36531000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-53775000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
321381000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-124325000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46152404
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44471844
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45888769
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44379924
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46152404
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44471844
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46780963
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44379924
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4200111
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11705960
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3309299
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11705960

Files In Submission

Name View Source Status
0001558370-21-013423-index-headers.html Edgar Link pending
0001558370-21-013423-index.html Edgar Link pending
0001558370-21-013423.txt Edgar Link pending
0001558370-21-013423-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
qure-20210930.xsd Edgar Link pending
qure-20210930x10q.htm Edgar Link pending
qure-20210930x10q_htm.xml Edgar Link completed
qure-20210930xex10d1.htm Edgar Link pending
qure-20210930xex31d1.htm Edgar Link pending
qure-20210930xex31d2.htm Edgar Link pending
qure-20210930xex32d1.htm Edgar Link pending
qure-20210930_cal.xml Edgar Link unprocessable
qure-20210930_def.xml Edgar Link unprocessable
qure-20210930_lab.xml Edgar Link unprocessable
qure-20210930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending